Cis-diamminedichloroplatinum (II) (cisplatin), given to pregnant rats at 5 mg/kg body weight (bw) is a trans placental carcinogen for fetal liver, kidney, nervous system and lung, resulting in tumor incidences of 22.5, 10.5, 6.1 and 7.5% respectively, in offspring grown to adulthood (B.A. Diwan et aL, 1995, Toxicol AppL Pharm., 132, 115). In this study, the capacity of cisplatin to pass through the placental barrier and bind covalently to DNA in maternal and fetal tissues was evaluated. Pregnant F344/NO rats were injected i.p. with single doses of 5, 10 or 15 mg cisplatin/kg bw at 18 days of gestation and sacrificed 24 h later. Cisplatin-DNA adducts were determined by dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA) using both High (90 pmol/^g DNA) and Low (0.50 pmol/ Jig DNA) Modified cisplatin-DNA standards and atomic absorbance spectrometry (AAS). The adduct quantities determined by the two DELFIAs varied in concert, but the DELFIA with Low Modified standard gave actual values similar to those observed with AAS. In maternal and fetal tissues, with the exception of placenta in one experiment and maternal kidney in another experiment, the extent of cisplatin-DNA adduct formation increased with dose. In maternal kidney, the low adduct levels observed at the 15 mg/kg dose may reflect kidney toxicity. Fetal kidney, liver and lung contained fewer cisplatin-DNA adducts than the corresponding maternal tissues. In contrast, at 5 and 15 mg/kg, fetal brain DNA contained higher adduct levels than maternal brain DNA. This study demonstrates the presence of DNA damage induced by cisplatin in multiple maternal and fetal rat tissues at tumorigenic doses of drug; the results are therefore consistent with the hypothesis that genotoxic mechanisms play an important role in the drug-induced tumor incidence.
Introduction
Ovarian cancer occurs during human gestation with a frequency of approximately one in 25 000 pregnancies (1). Pregnant ovarian cancer patients are often treated with single and multiple-agent chemotherapy protocols that employ ds-diamminedichloroplatinum (U) (cisplatin) or diamminecyclobutanedicarboxylatoplatinum (TJ) (carboplatin) (2) . These regimens have resulted in normal deliveries and healthy infants when cisplatin is administered after the first trimester of pregnancy (3, 4) . Since the infants born have not shown morphological abnormalities, and the mothers are typically cancer-free (3), the treatment is considered successful. However, because transplacental cisplatin exposure is tumorigenic in rodents (5-7) the possibility exists that these children may encounter problems later in life.
The antitumoral effects of platinum drugs are related to their chemical structure. cw-Isomers of cisplatin and various analogs are highly effective clinically and are known to damage DNA by forming covalent adducts (8, 9) . This interaction is apparently responsible for the toxicity of the drug. In the high chloride milieu of extracellular fluids, cisplatin remains in a non-reactive form, becoming activated intracellularly at low chloride concentrations. Initial binding is at the N 7 position of deoxyguanosine (dG*) forming a monofunctional adduct due to the loss of one chloride (9) . Subsequently, by hydrolysis of a second chloride ion, a bifunctional adduct is produced at the location of either two adjacent dGs or a dG with an adjacent 5'dA (10,11). The resulting intrastrand adducts, cw-diammineplatinum-
) comprise the major (>80% in vivo) portion of cisplatin binding to DNA (9, 12) . Less than 20% of the total platinum bound to DNA is in the form of monoadducts and DNA interstrand or DNA-protein cross links (9, 12) . The bifunctional intrastrand adducts are probably responsible for the major cisplatin genotoxicity by inhibition of DNA replication (13, 14) .
Cisplatin has been shown to be mutagenic (15) (16) (17) and tumorigenic in vivo in several rodent systems (5-7). A single drug exposure produced skin and lung tumors in mice and rats, respectively (5,7). In addition, in offspring of mice exposed transplacentally to one dose of cisplatin and grown to adulthood, neoplastic and preneoplastic lesions were observed in thymus, lung and kidney (18) . Similarly, offspring of pregnant rats exposed to a single dose of cisplatin developed kidney, liver, nervous system and lung tumors when grown to adulthood (19) .
The present study was designed to support the rat transplacental tumorigenicity experiments by investigating cisplatin-DNA adduct formation in maternal and fetal tissues after exposure to tumorigenic doses of cisplatin at 18 days of gestation. These experiments comprise an attempt to understand basic genotoxic mechanisms involved in rat transplacental tumorigenesis induced by a single dose of drug.
Materials and methods

Animals and exposures
Pregnant F344/NCr rats were provided by the Animal Production Area of the NCI-Frederick Cancer Research and Development Center. Animal care for A J.GIurgiovich el al this experiment was provided in accordance with the procedures outlined in the guide for the Care and Use of Laboratory Animals (NIH, Publication 86-23, 1995). Cisplatin was purchased from Sigma Chemical Co. (St Louis, MO), and dissolved in 2.5% sterile aqueous sodium chloride solution immediately prior to use. The animals were distributed into groups of three. For the first experiment cisplatin was given at 0, 5 and 10 mg/kg body weight (bw), and for the second experiment the doses used were 0, 5 and 15 mg cisplatin/kg bw. For each experiment the three control rats received 2.5% saline solution. Exposures comprised a single intraperitoneal injection on day 18 of pregnancy, with sacrifice of mothers and fetuses 24 h later.
Tissue preparation and DNA extraction
At the time of sacrifice each mother carried an average of seven or eight live fetuses, with the exception of one animal found in the very early stages of fetal resorption. Tissues from mothers and fetuses were collected, weighed and rapidly chilled on wet ice before freezing in liquid nitrogen. Organs were obtained only from fetuses at the 5 and 10 mg/kg bw doses in the first experiment, and from mothers and fetuses at the 5 and 15 mg/kg bw doses in the second experiment. Maternal tissues comprised kidney, liver, lung, brain, uterus, ovary and heart. Because the tissue quantity per fetus was so small, similar organs (e.g. all the livers) from the animals in one litter were combined for DNA extraction and analysis. Organs obtained from the fetuses were kidney, liver, lung, brain and placenta.
For DNA extraction, tissues were thawed, homogenized and nuclei prepared. DNA was obtained by CsCl buoyant density gradient centnfugation, dialyzed for 24 h against distilled water to remove CsCl and quantified by absorbance at 260 nm as previously described (20).
Cisplatin-DNA adduct measurement by dissociation enhanced lanlhanide Fluoroimmunoassay (DELFIA)
Cisplatin-DNA adducts were determined by DELFIA, an adaptation of the enzyme-linked immunosorbent assay (ELISA) (21) (22) (23) . The assay was performed using microtiter plates coated with 0.30 ng of the High Modified cisplatin-DNA standard, having 90 pmol cisplatin/ng DNA (3% modification), as determined by atomic absorbance spectrometry (AAS). Plates were blocked with fetal calf serum for 60 min at 37°C. Each well contained 35 ng of sample or standard curve DNA, and samples were assayed three times using triplicate experimental and one control well(s) per assay. Rabbit antiserum elicited against cisplatin-DNA (4.3% modified) was used as primary antibody (24, 25) at a dilution of 1:120 000 in 2% fetal calf serum. Biotinylated goat anti-rabbit IgG (Vector, Burlingame, CA), at a dilution of 1:20 000 in 1% fetal calf serum, was used as secondary antibody. Subsequent incubations were with EU-labeled streptavidin, diluted 1:2500 in Wallac Assay Buffer (Wallac, Gaithersburg, MD) and Wallac Enhancement solution. Fluorescence was read by DELFIA Research Fluorometer (Wallac) at 614 nm.
Previous expenments have demonstrated (22, 26 ) that a consistent property of antisera elicited against carcinogen-modified DNA is preferential recognition of the immunogen DNA, modified to 1-4 adducts in 100 nucleotides, as compared to the biological sample DNA that may have 1 adduct in 10 7 nucleotides. The changes in conformation at different modification levels are reflected in antibody recognition and require that a cisplatin-DNA standard modified in the same range as the biological samples (Low Modified) be used as standard to compare with biological samples for quantitative adduct values. For the cisplatin-DNA immunoassays, adduct values obtained with Low Modified cisplatin-DNA standards [0.3-0.8 pmol platinum (Pt)/|ig DNA] were shown to be similar to diose determined by AAS (22) . In these experiments Low Modified (0.5 pmol Pt/|ig DNA) cisplatin-DNA standards were used in each assay. The 50% inhibition for 40 Low Modified standard curves was 0.59 ± 0.04 pmol Pt. The detection limits were at 0.7 fmol/|ig DNA for the first experiment and 2 fmol/|ig DNA for the second experiment.
Atomic absorbance spectrometry with Zeeman background correction DNA samples were assayed once for content of total elemental platinum bound to DNA using AAS with Zeeman background correction, as previously described (25, 27) . The amounts of DNA available for this assay ranged from 41 to 210 |ig. For each analysis, DNA was assayed in a 250 |il sample volume, and the standard curve of elemental platinum was linear between 3.75 and 100 pmol Pt. The lower limit of sensitivity was in the range of 1-2 fmol Pt^g for 125-250 |ig of DNA, but the AAS was less sensitive when available quantities of DNA were smaller.
Results
This study was designed to compare DNA damage in maternal tissues and transplacentally-exposed fetal tissues after a single dose of cisplatin. Two experiments were performed using different doses of cisplatin in F344/NCr pregnant rats. In the or livers at the higher dose one litter was negative and was given a value half way between zero and the detection limit. 1.9 ± 0.4 "Each tissue was assayed three times by DELFIA to obtain a mean value. Data presented are mean + SE for three pregnant rats. b In cases where one or two out of the three samples were not detectable, these samples were assigned a value half-way between 0 and the limit of detection and averaged with the positive values for statistical purposes. Three samples were not detectable (ND). The detection limit for these assays was 2 fmol/|ig DNA.
first experiment pregnant rats were exposed at 0, 5 and 10 mg cisplatin/kg bw and only DNA from fetal tissues was assayed. In the second experiment the doses chosen were 0, 5 and 15 mg/kg bw and adducts were investigated in DNA from multiple maternal and fetal tissues. In both experiments cisplatin was administered on day 18 of gestation, and tissues were taken 24 h later. In the first experiment only fetal tissues were obtained, and data for adduct values determined by cisplatin-DNA DELFIA with both High and Low Modified standard curves are presented in Table I . At the 5 mg/kg dose placenta and brain had measurable adduct levels but adducts were undetectable in kidney, liver and lung. For the 10 mg cisplatin/kg dose, adducts were detectable in all fetal tissues with the exception of lung. A dose-response was observed in brain, kidney and liver using both High and Low Modified standard curves.
In the second experiment both maternal (Table IT) and fetal "Tissues from all the pups in one litter were pooled and the DNA assayed three times by DELFIA. Values presented are mean + SE from three different litters corresponding to the pregnant rats in Table II.   b In cases where one or two out of the three samples were not detectable, these samples were assigned a value half-way between 0 and the limit of detection and averaged with the positive values for statistical purposes. Three samples were not detectable (ND). The detection limit for these assays was 2 fmol/u.g DNA. (Table HI) tissues were obtained from pregnant rats exposed to cisplatin at 5 and 15 mg/kg bw. A dose-response was observed in all tissues except maternal kidney, which contained similar adduct concentrations at both doses. This may have occurred because kidney is a target for cisplatin toxicity and 15 mg/kg is a highly toxic dose. A comparison of cisplatin-DNA adducts in maternal and fetal target tissues for tumorigenesis revealed that most maternal tissues contained 2-to > 10-fold higher adduct levels than the corresponding fetal tissues ( Figure 1A and B). Brain tissue was the exception, since fetal brain contained higher adduct levels than maternal brain at both doses investigated. Figure 1 also shows that the comparison of biological samples using DELFIA with both High and Low Modified standards gives parallel and internally consistent results, even though the actual numbers differ.
A comparison of values obtained by DELFIA with Low Modified cisplatin-DNA standard and AAS is shown in Table  IV . This comparison is of interest for reasons explained in Shamkhani et al. (22) . Briefly, the DELFIA with Low Modified standard gives values similar to those obtained using the AAS, for total platinum bound to the DNA, because the antibody recognition of standard and biological sample is matched. A comparison of values determined by AAS and DELFIA with Low Modified standard (Table IV and Figure 2 ) shows a correlation coefficient by linear regression of 0.76, indicating good correspondence between the two techniques. The largest discrepancy is for maternal liver at 15 mg cisplatin/kg bw where there were only two samples for AAS, one of which had a small quantity of DNA. Unlike the DELFIA, it is generally not possible to assay a DNA sample more than once by AAS because of the large quantity of DNA required.
Discussion
These experiments demonstrate that in pregnant rats exposed to cisplatin on day 18 of gestation and sacrificed 24 h later, the drug has widespread distribution and binding to DNA in multiple maternal and fetal tissues. The experimental design used here was the same as that employed by Diwan et al. (19) who found tumorigenicity in multiple organs of rats at 79 weeks of age after transplacental exposure to a single dose of 5 mg cisplatin/kg bw. Diwan et al. found tumor incidences of 22.5, 10.5, 6.1 and 7.5% in liver, kidney, nervous system and lung, respectively, and an increased renal cell adenoma incidence of 45% with postnatal sodium barbital promotion (19) . The DNA adduct data reported here are consistent with the hypothesis that genotoxic mechanisms may play an important role in the carcinogenic influence of this drug because the highest DNA adduct levels were observed in the most susceptible tissues. Transplacental passage of cisplatin, with unknown genotoxicity, was previously reported by Stewart et al. (28) in human placenta and fetal tissues from a patient undergoing therapeutic abortion after 4 days of cisplatin therapy. More recently cisplatin DNA adducts were found in human placenta and maternal blood from a patient treated with cisplatin and carboplatin for three doses beginning at 20 weeks of pregnancy (22) . Because the question of DNA adduct formation in human fetal tissues was unable to be resolved, transplacental exposures were initiated in the patas monkey. Cisplatin was shown to cross the placenta and bind to multiple tissues of monkey fetuses exposed transplacentally during the last trimester of gestation (22) . Similar to the rat experiments reported here, the patas monkey dams formed more adducts than their fetuses and adduct levels in fetal brain were particularly high (22) .
In maternal kidney DNA the adducts formed with 5 mg cisplatin/kg bw were similar to those obtained with 15 mg cisplatin/kg BW. This lack of a dose-response could be explained by kidney toxicity since the higher dose is greater than the LD50 (29, 30) . Since 50% of the total dose of platinum administered to a rat by injection will be excreted by the kidneys 24 h later, kidneys are a major site for cisplatin detoxification and toxicity (31) . Therefore, it was not surprising to find that, of all tissues studied, maternal kidneys contained the highest levels of cisplatin DNA adducts.
Although persistence of cisplatin DNA adducts was not investigated here, cisplatin-DNA adducts have been observed in gonads and kidneys of rats exposed to 5 mg cisplatin/kg bw on post-exposure days 7 and 14 (32) . In addition, in autopsy tissues from cancer patients platinum-DNA adducts were detectable in multiple tissues several months after the ultimate chemotherapy treatment (32) . Perinatal adduct persistence will be investigated in future experiments, although it is possible that the accelerated proliferation rate of fetal tissues may contribute to adduct turnover and make such measurements difficult.
The DNA adduct data reported here are consistent with the hypothesis that genotoxic mechanisms may play an important role in the carcinogenic influence of this drug because the highest DNA adduct levels were observed in the most susceptible tissues. These studies are particularly important because cisplatin and carboplatin are in use as standard of care for women discovered to have ovarian cancer during pregnancy. Whereas human infants exposed transplacentally to this drug have been bom morphologically normal (3, 4, 33) , it is not yet possible to rule out deleterious effects of drug exposure that may occur later in life.
